BPG is committed to discovery and dissemination of knowledge
Editorial
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Apr 7, 2026; 32(13): 115440
Published online Apr 7, 2026. doi: 10.3748/wjg.v32.i13.115440
Risk stratification of gastric neuroendocrine tumors in autoimmune gastritis: Evaluating the clinical value of an integrated clinical-endoscopic model
Qing-Qing Yu
Qing-Qing Yu, Clinical Research Center, Jining No. 1 People's Hospital, Jining 272000, Shandong Province, China
Author contributions: Yu QQ contributed to the discussion, design of the manuscript, the writing, and editing the manuscript, illustrations, and review of literature.
Conflict-of-interest statement: The author reports no conflicts of interest in this work.
Corresponding author: Qing-Qing Yu, Professor, Clinical Research Center, Jining No. 1 People's Hospital, No. 6 Jiankang Road, Jining 272000, Shandong Province, China. yuqingqing_lucky@163.com
Received: October 20, 2025
Revised: December 4, 2025
Accepted: January 28, 2026
Published online: April 7, 2026
Processing time: 158 Days and 18.2 Hours
Core Tip

Core Tip: Autoimmune gastritis induces gastric neuroendocrine tumors through a multistep process involving oxyntic mucosal destruction, hypergastrinemia, and enterochromaffin-like cell proliferation. Integrated clinical-endoscopic models utilizing machine learning (e.g., Boruta algorithm) outperform single-parameter approaches, with key predictors including atrophy severity, gastrin levels, and Helicobacter pylori history. These models enable personalized risk-adapted surveillance, inform vitamin B12 chemoprevention, and improve prognostic stratification by incorporating endoscopic and proliferative indices. Current limitations include single-center bias and incomplete molecular integration; future development requires multicenter validation and multimodal biomarkers.